Altasciences
Altasciences is recorded as a service provider in 70 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 70 trials · Latest update first
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19
Sponsor Atea Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- A global amendment increased the planned eligible sample from 1500 to approximately 2510 because low global COVID-19 hospitalization and death rates reduced endpoint event rates.
- Rapid enrollment prevented the planned interim analysis after 65% of subjects completed Day 29 assessments; consequently, adolescent enrollment was not recommended and no pediatric subjects were enrolled.
- Of 218 screen failures, 177 were due to failure to meet entry criteria.
- Enrollment was concentrated in North America (1811/2285 subjects), whereas Europe enrolled 57 subjects, Asia 170 subjects, and other countries 247 subjects.
These findings describe the trial, not the service provider’s performance or responsibility.
A Randomized, Blinded, Placebo-Controlled, Phase 1 Single Ascending Dose Study in Healthy Adult Male Volunteers and an Open-Label Multiple Ascending Dose Study with Long-Term Extension in Pediatric SMA Participants Previously Treated with Onasemnogene Abeparvovec (Zolgensma™) to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115.
Sponsor Biogen Idec Research Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Randomized, Double-blind, Placebo‑controlled, Dose‑ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mellitus
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn’s Disease
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Adult Participants with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-Based Therapy
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-1)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-2)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease
Sponsor Janssen Cilag International
- Start (EU)
- Latest update
- Estimated end
A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants with Congenital Adrenal Hyperplasia
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- A protocol amendment added health-authority-requested exclusion criteria, including contraception, hypersensitivity, judicial commitment, and adrenal-insufficiency-risk criteria, as well as expanded dietary and sleep-related lifestyle restrictions.
- A regional amendment added a morning-dosing cohort with gradual glucocorticoid dose reduction between Weeks 2 and 10, weekly follow-up, monitoring for glucocorticoid-withdrawal symptoms, and criteria to pause glucocorticoid reduction.
- A later regional amendment added guidance for potential interactions with CYP3A4/5 substrates.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-1)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.
Sponsor Inhibikase Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis
Sponsor Janssen Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Altasciences?
The 2026-10-09 snapshot links Altasciences to 70 distinct CTIS trials. Recorded services include Laboratory services, covering PK and Immunogenicity analyses, PK analysis, PK and immunogenicity sample testing, among 21 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Altasciences?
The most frequently recorded therapeutic areas are Metabolic Disorders, Endocrinology, Immunology, Gastroenterology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Altasciences conducted?
The linked trials record locations in 26 countries, including Germany, Spain, Poland, Italy, France. These are trial locations, not confirmed office locations or countries where Altasciences delivered services.
What can this page tell me about Altasciences's trial experience?
Browse 70 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Altasciences. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Altasciences Compagnie Inc.
- Altasciences Company Inc.